Episódios
-
Today Iâm talking with Dr. Karl Sjostrand, with Progenics. Progenicsâ is developing radiolabeled small molecules that bind to specific receptors, enzymes and proteins in the body that are altered during the evolution of disease.
Dr. Sjostrand and colleagues recently presented a study at the Society of Nuclear Medicine and Molecular Imaging annual meeting, entitled: Automated detection and quantification of prostatic PSMA uptake in SPECT/CT using a deep learning algorithm for segmentation of pelvic anatomy. Theyâve developed a radiolabeled probe: 99mTc MIP-1404 (1404), a prostate-specific membrane antigen (PSMA) targeted imaging agent is currently under investigation for the detection of clinically significant disease in prostate cancer. They concluded that a fully automated and fast algorithm for quantification of 1404 uptake in the prostate was demonstrated.
Check out aimedicinenews.com
I have a couple of new courses on Udemy, an online platform with low cost courses in all kinds of topics. If you type in âEmma Nicholsâ, youâll pull up my courses. The latest ones are Cancer Biology 101, How to Read and Interpret a Scientific Paper, and Freelance Medical Writing as a Career Choice. To check those out, just go to Udemy.com (Udemy.com) and type in âEmma Nicholsâ to pull them up.
-
In this episode, I talk to Dr. William Karnes with the University of California, Irvine about an AI-based colonoscopy solution called Qualoscopy. Qualoscopy auto-documents procedure reports and integrates with electronic health records. The goal is to improve colonoscopy efficacy and provide precise documentation. According to Dr. Karnes good clinicians want to provide the highest level of care for their patients and avoid redundant paperwork. âQualoscopy was designed from the ground up to make this a reality for all colonoscopists."
I have a couple of new courses on Udemy. Udemy is an online platform with low-cost courses in all kinds of topics. If you type in âEmma Nicholsâ, youâll pull up my courses. The latest ones are Cancer Biology 101, How to Read and Interpret a Scientific Paper, and Freelance Medical Writing as a Career Choice. To check those out, just go to Udemy.com (Udemy.com) and type in âEmma Nicholsâ to pull them up.
-
Estão a faltar episódios?
-
In this episode, I talk to Emilio Galan who is co-founder and president of Robin Healthcare. Robin Healthcare is a health-technology company providing a smart assistant device that frees up physicians to focus on the patient. The company has developed a HIPAA-compliant device that sits in the clinic room and uses both human and artificial intelligence (A.I.) to produce clinical notes.
I have a couple of new courses on Udemy.com. Udemy is an online platform with low cost courses in all kinds of topics. If you type in âEmma Nicholsâ, youâll pull up my courses. The latest ones are Cancer Biology 101, How to Read and Interpret a Scientific Paper, and Freelance Medical Writing as a Career Choice.
-
In this episode, I talk to Kimberly Powell, VP Healthcare & AI Business Development at NVIDIA. She talks about the invention of the graphics processing unit by NVIDIA over 20 years ago, which revolutionized computer graphics and has now become central to AI-based medical imaging applications, among other things.
In early June 2018 (about a week before this recording), NVIDIA, IBM, and the DoE Oak Ridge National Laboratory unveiled the worldâs fastest supercomputer. This is the first time since 2012 that a US-based supercomputer has made first place on the list of world supercomputers. Summit features 4,608 compute servers with two 22-core IBM Power9 chips and six Nvidia Tesla V100 GPUs each as well as over 10 petabytes of memory. As a test, the Summit conducted an AI-based genomic analysis and was able to achieve 1.88 exaflops of computing, something that has never been done before, according to Powell.
I also talk with Ms. Powell about what she expects in the near, medium, and long-term future with respect to NVIDIA's contributions and outcomes in healthcare. Itâs pretty exciting.
Brought to you by Nascent Medical. For assistance with medical writing, please email [email protected].
Check out Dr/ Nicholsâ new course on Udemy: How to Read and Interpret a Scientific Paper
Visit our website at aimedicinenews.com
-
In this episode, I talk to Guy Newing, who is the CEO of Kinect (also, Kinect Hub). http://www.kinecthub.com. Kinect is working to redefine healthcare systems in low income countries. In our interview, Mr. Newing discusses some of the advantages of a blockchain and AI-based medical record system, the challenges they are facing to implement this system, and their ongoing efforts to improve healthcare reporting in low-income countries.
This podcast is brought to you by Nascent Medical. For assistance with medical writing, please email [email protected].
-
In this episode, I talk to Dr. Suvas Vajracharya, CEO and Founder, Lightning Bolt Solutions, Inc, which was founded in 2002. The company is dedicated to creating balanced and efficient hospital workforces through optimized physician scheduling. According to their LinkedIn profile, across the U.S., Canada, Japan, and Australia, Lightning Bolt manages over 3 million shift hours each month, scheduling 20,000 clinicians at 350 healthcare organizations.
-
Today Iâm talking with Dr. Claire Novorol who is Co-founder and Chief Medical Officer at Ada. Ada is an AI-based app that enables people to self-assess their symptoms and identify possible causes and appropriate next steps. She discusses how and why she founded the company as well as the role of the Ada app in current healthcare practice.
https://ada.com/app/
-
In this episode, I talk to Dr. Chris Mansi, who is CEO and cofounder of the Silicon Valley based healthcare AI company Viz. Viz is aiming to improve acute medical care by reducing the time spent triaging the care of patients with life-threatening diseases such as stroke. Their main products to date are the Viz LVO (large vessel occlusion) and Viz CTP (CT perfusion) platforms. Dr. Mansi talked with me about how and why the company got started and what they see as their future directions.
Music credit: http://freemusicarchive.org/music/Split_Phase/Compendium/split_phase-31-cloudwalker
-
Drs. John Dillon and Paul A. Friedman with the Mayo Clinic recently described their strategy for using AI to create a âbloodless blood testâ, a new way of detecting fluctuations of blood potassium levels that patients can perform at home without drawing blood. They described the strategies they used for the development of this test in a recent article in the Harvard Business Review. In our interview, I asked them to elaborate further on the development of this test and discuss some of the limitations as well as the implications for other potential biomarker/symptom correlations that may be measurable with similar approaches.
John J. Dillon, MD, is the director of Mayo Clinic Dialysis Services in the Division of Nephrology & Hypertension and is the former director of the Mayo Clinicâs Nephrology Hospital Practice and Paul A. Friedman, MD, is the chair of the Department of Cardiovascular Medicine at Mayo Clinic in Rochester, Minnesota. Previously, he served as director of the Mayo Clinicâs Cardiac Implantable Device Lab.
-
In this episode, I talk with Michael Abramoff, MD, PhD, founder, president, and director of IDx (https://www.eyediagnosis.net/idx-dr). His company has developed an automated diabetic retinopathy (DR) diagnostic solution, IDx-DR, which received expedited review under the FDAâs Breakthrough Devices program following a pivotal clinical trial. The trial was conducted at ten primary care sites across the U.S., and included about 900 subjects who underwent the IDx-DR exam. Last month, the FDA permitted marketing of the software program, which uses AI to determine whether further followup for DR is needed.
IDx-DR is the first device authorized for marketing that provides a screening decision without the need for a clinician to also interpret the image or results, which makes it usable by health care providers who may not normally be involved in eye care. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm604357.htm
â
-
In this episode, I talk with Brigham Hyde, Ph.D., who is CEO of Precision Health AI. He talks about their recently launched Eureka Healthâą Oncology AI platform that leverages EMR data to provide practical AI applications built for oncology.
Some examples Dr. Hyde discusses include predicting chemotherapy induced neutropenia with high accuracy, which is considered a hifi application, all the way to the âoncostageâ algorithm that deals on the back end with consistency across platforms in describing staging. This is considered a low fi application that makes data more usable and analyzable.
https://precisionhealth.ai/
https://www.businesswire.com/news/home/20180301005271/en/Precision-Health-AI-Launches-Eureka-Health%E2%84%A2-OncologyCheck out Dr. Nichols other (daily) podcast New FDA Approvals. Newfdaapprovals.com
-
In this week's episode I talk to Professor Peter Donnelly, CEO and founder of Genomics PLC, a group of leading geneticists and data scientists based near Oxford University, UK, and leader of The Wellcome Centre for Human Genetics. Researchers at Genomics, PLC, are starting to link genomic data with electronic health records to glean previously unseen insights into genetics and health outcomes. He says there a tsunami of genetic information and within 10 to 15 years there will be a billion people on the planet who have had their genomes sequenced and linked health data, which he says is an "enormous opportunity." In the last year, he says, their researchers have really had a breakthrough in terms of being able to analyze the data to get real insights about human biology. "We are trying to learn about the human wiring diagram; we're starting to see a window into human biology that is incredibly exciting."
-
Today I talk to Ioannis Tarnanas, who is Founder & Chief Scientist (CSO) at Altoida.
According to Crunchbase, Altoida Medical Device (AMD) provides health care professionals objective measurements of cognitive performance, and is indicated for use as an adjunctive tool to aid in evaluation perceptual and memory function in patients 55 to 95 years old. AMD is a FDA class II medical device enabling:
Early screening for cognitive decline patterns specific for prognosis (at risk) or classification of Mild Cognitive Impairment.
They are seeking to use this device as a secondary endpoint for clinical trials and to expand outside of AD, as well as to become a data platform to enable collection and discover new targets.
Please check out Dr. Nichols' other podcast, New FDA Approvals. This shorter podcast comes out 5 days a week, Monday through Friday, and covers the real time happenings coming out of the FDA. It is meant to inform healthcare providers, medical writers, and other medical information specialists.
-
Kevin Harris, CEO of Curemetrix, describes how researchers at his company took space imaging technology and applied it to the medical field, specifically mammography. âIf we get this right, itâs breast cancer⊠we can really have an impact,â he says. They may be able to find cancer earlier; they were able to look 6 years earlier and find anomalies that were missed by doctors and eventually grew into cancers. Harris says the technology may really help improve outcomes for patients. They are in the process of getting FDA approval for their product CMAssist. Doctors can currently test it out for investigational uses prospectively and can also provide retrospective data for analysis.
Please subscribe, rate and review if you like this podcast. Thank you! The podcast website is http://aimedicinenews.com
-
Austin Caudle, Associate Director, R&D Solutions at IQVIA, describes how the company uses data to help clients develop clinical trial protocols and identify hard-to-find patients for clinical trials. âA lot of people donât really realize the scale and complexity of working with data,â he says. âWe spent the last 4 years an advanced healthcare data cloud resulting in 300 technology patents and patent applications.â Find out more.
Please visit this podcastâs website at http://aimedicinenews.com
Contact [email protected] for your medical writing needs.
-
Today, I talk with Hannes SmĂĄrason, the CEO and cofounder of WuXiNextCODE, and Dr. Edward Farmer, the companyâs Executive VP, Communications & New Ventures. They talk about why their company is laser focused on the China market and their predictions for the future directions of their global platform for genomics big data.
-
In this episode I talk with Carla Leibowitz, who is the head of Strategy and Marketing at Arterys.
She describes the technology they have created at Arterys: AI-based cardiology, lung, and liver applications.
Arterys received 510(k) clearance from the U.S. Food and Drug Administration for its software in November 2016. This clearance allowed the Arterys product to be used in clinical settings for the quantification of cardiac flow, which includes 4D flow and 2D Phase Contrast workflows, and cardiac function measurements.
She discusses how clinicians can interact with Arterys and onboard the software. She also points out that AI isn't going to be taking clinician jobs. Rather, they are trying to give them superpowers!
Check out this podcast's website AIMedicineNews.com
Pease check out Emma's other podcast, New FDA Approvals. This shorter podcast comes out 5 days a week, Monday through Friday, and covers the real time happenings coming out of the FDA. It is meant to inform healthcare providers, medical witers, and other medical information specialists.
-
Dr. Emma Nichols interviews Dr. Tim Guilliams, co-founder of Healx.io and he explains how they reduce the cost of identifying effective drugs for rare diseases, which affect 350 million individuals worldwide, with 95% having no effective treatment. They start with approved drugs and nutraceuticals and also look at combinations of drugs using artificial intelligence/deep learning. The company works closely with organizations and patient communities to help move their findings forward. So far, he says, every project has been successful. They have identified candidates for Fragile X syndrome and CD5 syndrome (?), which will be tested in humans soon. Thereâs also a triplet combination that has shown very high efficacy in severe diarrhea. âThereâs never been a more exciting time for drug discovery,â Dr. Guilliams says.
Just a quick note, I say in the recording that the website is healx.com, but itâs actually healx.io.
Please check out the website for this podcast which is aimedicinenews.com
-
AI in optical biopsy for GI applications
AI4GI CEO Dr. Michael Byrne talks about optical biopsy using deep learning techniques.
They built their startup in a very different way: they tried engaging the top key opinion leaders in GI and also AI, such as one of the founders of deep learning, Dr. Yoshua Bengio, from the outset. They built the team âvery strategicallyâ he says.
Currently, there are 20 million screening colonoscopies a year in the US alone. Each time a polyp is removed, it has to be sent to a lab, and it delays giving an answer to the patient for maybe a week or two.
The level of performance of the AI4GI system is about 95%, which exceeds that of the best human attempts for diagnosing cancerous vs. non-cancerous polyps. Plus, itâs essentially in real time, which means no anxious waiting for a couple of weeks while the biopsy results come back.
Check out AImedicinenews.com the website for this podcast
Also, check out NewFDAapprovals.com, Emma's daily podcast talking about all the happenings coming out of the FDA.
-
The founders of ThinkGenetic describe how the founder's genetic condition, cutis laxis, prompted them to start thinkgenetic.com. They used the power of data collection and AI/machine learning to create a symptom matcher to help diagnose rare genetic diseases.
Interviewees:
Dave Jacob, CEO and Co-Founder, ThinkGenetic Dawn Jacob Laney, MS, CGC, CCRC, Co-Founder, ThinkGenetic Ruth O'Keefe, Director of Marketing, ThinkGenetiAI Medicine news â aimedicinenews.com Precision Medicine World conference, Silicon Valley Jan 22-24. http://www.pmwcintl.com/2018sv/program/
- Mostrar mais
